SRR10899973
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- COMPLEMENT+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- HYPOXIA+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- ANGIOGENESIS+0.400
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- PROTEIN_SECRETION-0.300
- DNA_REPAIR-0.200
- SPERMATOGENESIS-0.200
- PEROXISOME-0.100
- WNT_BETA_CATENIN_SIGNALING-0.100
- ADIPOGENESIS+0.000
- BILE_ACID_METABOLISM+0.000
- FATTY_ACID_METABOLISM+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_J1AB8PMA | Med | Medulloblastoma | 0.926 |
| 2 | SRR10900576 | — | — | 0.895 |
| 3 | SRR1488836 | GTEX | — | 0.895 |
| 4 | ERR2208908 | — | — | 0.890 |
| 5 | MDT-AP-2086 | Med | Medulloblastoma | 0.890 |
| 6 | SRR10900559 | — | — | 0.888 |
| 7 | EPT0509 | EPN | EPN Tumor | 0.880 |
| 8 | SRR1453932 | GTEX | — | 0.878 |
| 9 | s0122206 | — | — | 0.875 |
| 10 | DRR168605 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.600 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| HYPOXIA | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |